Zytoon Ashraf Anas, Ishii Hiroshi, Murakami Koji, El-Kholy Mohamed Ramdan, Furuse Junji, El-Dorry Ahmed, El-Malah Adel
Radiology Department, Faculty of Medicine, Menoufiya University, Shebin E1-Koom, Menoufiya, Egypt.
Jpn J Clin Oncol. 2007 Sep;37(9):658-72. doi: 10.1093/jjco/hym086. Epub 2007 Aug 31.
Despite the high complete necrosis rate of radiofrequency ablation (RFA), tumor recurrence, either local tumor recurrence or new tumor formation, remains a significant problem. Purpose of this study is to evaluate the pattern and risk factors for intrahepatic recurrence after percutaneous RFA for hepatocellular carcinoma (HCC).
We studied 40 patients with 48 HCCs (< or = 3.5 cm) who were treated with percutaneous RFA. The mean follow-up period was 24.1 +/- 15.7 months. We evaluated the cumulative disease-free survival of overall intrahepatic recurrence, local tumor progression (LTP) and intrahepatic distant recurrence (IDR). Thirty host, tumoral and therapeutic risk factors were reviewed for significant tie-in correlation with recurrence: age; gender; whether RFA was the initial treatment for HCC or not; severity of liver disease; cause of liver cirrhosis; contact of tumor to major hepatic vessels and liver capsule; degree of approximation of tumor to the liver hilum; ablation time; degree of benign pre-ablational enhancement; sufficient safety margin; tumor multinodularity; tumor histological differentiation; tumor segmental location; maximum tumor diameter; degree of tumor pre-ablational enhancement at arterial phase CT, MRI or CT-angiography; and laboratory markers pre- and post-ablation (AFP, PIVKA II, TP, AST, ALT, ALP and TB).
The incidence of overall recurrence, LTP and IDR was 65, 23 and 52.5%, respectively. The cumulative disease-free survival rates were 54.6, 74.8 and 78.3% at 1 year, 27.3, 71.9 and 46.3% at 2 years and 20, 71.9 and 29.4 at 3 years, respectively. Univariate and multivariate analysis showed that the significant risk factors for LTP were: tumor size > or = 2.3 cm, insufficient safety margin, multinodular tumor, tumors located at segments 8 and 5, and patient's age > 65 years (P < 0.05). No significant risk factor relationship for IDR could be detected.
Our results would have clinical implications for advance warning and appropriate management of patients scheduled for RFA. Patients at risk of LTP should be closely monitored in the first year. Furthermore, regular long-term surveillance is essential for early detection and eradication of IDR.
尽管射频消融术(RFA)的完全坏死率很高,但肿瘤复发,无论是局部肿瘤复发还是新肿瘤形成,仍然是一个重大问题。本研究的目的是评估经皮射频消融治疗肝细胞癌(HCC)后肝内复发的模式和危险因素。
我们研究了40例患有48个肝细胞癌(直径≤3.5 cm)的患者,这些患者接受了经皮射频消融治疗。平均随访期为24.1±15.7个月。我们评估了总体肝内复发、局部肿瘤进展(LTP)和肝内远处复发(IDR)的累积无病生存率。回顾了30个宿主、肿瘤和治疗相关的危险因素,以确定与复发的显著关联:年龄;性别;RFA是否为HCC的初始治疗方法;肝病严重程度;肝硬化病因;肿瘤与主要肝血管和肝包膜的接触情况;肿瘤与肝门的接近程度;消融时间;消融前良性强化程度;足够的安全 margins;肿瘤多结节性;肿瘤组织学分化;肿瘤节段位置;最大肿瘤直径;动脉期CT、MRI或CT血管造影时肿瘤消融前强化程度;以及消融前后的实验室指标(AFP、PIVKA II、TP、AST、ALT、ALP和TB)。
总体复发、LTP和IDR的发生率分别为65%、23%和52.5%。1年时累积无病生存率分别为54.6%、74.8%和78.3%,2年时分别为27.3%、71.9%和46.3%,3年时分别为20%、71.9%和29.4%。单因素和多因素分析表明,LTP的显著危险因素为:肿瘤大小≥2.3 cm、安全 margins不足、多结节肿瘤、位于第8和第5段的肿瘤以及患者年龄>65岁(P<0.05)。未检测到与IDR有显著危险因素关系。
我们的结果对计划接受RFA治疗的患者的预警和适当管理具有临床意义。有LTP风险的患者在第一年应密切监测。此外,定期长期监测对于早期发现和根除IDR至关重要。